This study demonstrates that CXCL9, IL2RB, and SPP1 may serve as potential biomarkers for the diagnosis of the co-morbidity patterns of AS and NASH and as potential targets for drug therapy. This evidence concerns the gene CXCL9 and metabolic dysfunction-associated steatohepatitis.